Search Results
May 22, 2026, 06:30 ET STL's subsidiary announces supply agreement valued over $1Bn with a Hyperscaler for AI-Ready Data Center build-outs
With its in-house R&D expertise, STL has brought novelty to fiber optic designs and built AI-ready networks. STL's innovation is driven by co-creation with customers and
More news about: Sterlite Technologies Ltd. (STL)
May 22, 2026, 06:02 ET 14 Press Releases You Need to See This Week
America's first pure-play quantum foundry. This initiative represents one of the most significant commitments by the U.S. Government to date in quantum R&D to position the United States to manufacture most of the world's quantum wafers.
More news about: PR Newswire
May 22, 2026, 06:00 ET Yuchai's Flywheel Range Extension Technology Arrives in Hong Kong SAR, Setting a New Benchmark for Green Mobility
strengthening collaboration across the industrial chain to deliver sustainable powertrain solutions to domestic and global markets. Our continued R&D efforts will help drive the low–carbon transformation of urban transportation and contribute to the future development of green mobility."About
More news about: China Yuchai International
May 22, 2026, 05:00 ET Hisense wprowadza serię UR8 z naturalnym i wiernym odwzorowaniem kolorów, czyniąc technologię RGB MiniLED nowej generacji dostępną dla kolejnych gospodarstw domowych
QINGDAO, Chiny, 22 maja 2026 r. /PRNewswire/ -- Hisense, czołowa marka w branży globalnej elektroniki użytkowej i sprzętu gospodarstwa domowego, zaprezentowała dziś serię UR8 - dostępną cenowo linię telewizorów RGB MiniLED,
More news about: Hisense
May 22, 2026, 04:45 ET Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet
https://www.doktorn.com/sjukdomar/munherpes-herpes-simplex-orsak-symtom-behandling/Olsson J, Kok E, Adolfsson R, Lövheim H, Elgh F. Herpes virus seroepidemiology in the adult Swedish population. Immunity & Ageing. 2017;14:10.Virono® Summary of Product
More news about: Navamedic ASA
May 22, 2026, 02:52 ET Invitation to presentation of Sectra's year-end report 2025/2026
https://news.cision.com/sectra/r/invitation-to-presentation-of-sectra-s-year-end-report-2025-2026,c4350449
More news about: Sectra
May 22, 2026, 02:49 ET ZINZINO AB (PUBL.): INTERIM REPORT Q1 2026
https://news.cision.com/zinzino/r/zinzino-ab--publ--interim-report-q1-2026,c4351838The following files are available for download:
More news about: Zinzino
May 22, 2026, 02:49 ET Betolar and Enersense Launch Commercial Cooperation to Protect Electrical Substations
https://news.cision.com/betolar-oyj/r/betolar-and-enersense-launch-commercial-cooperation-to-protect-electrical-substations,c4351855
More news about: Betolar Oyj
May 22, 2026, 02:26 ET Skanska appointed preferred bidder as Master Developer of the Penn Station Transformation Project in New York, USA
https://news.cision.com/skanska/r/skanska-appointed-preferred-bidder-as-master-developer-of-the-penn-station-transformation-project-in,c4351857The following files are available for download:
More news about: Skanska
May 22, 2026, 02:15 ET Husqvarna Group again recognized as one of Europe's Best Employers
https://news.cision.com/husqvarna-group/r/husqvarna-group-again-recognized-as-one-of-europe-s-best-employers,c4351715The following files are available for download:
More news about: Husqvarna Group
May 22, 2026, 02:15 ET Implantica publishes Interim Report January - March 2026 (Q1)
https://news.cision.com/implantica/r/implantica-publishes-interim-report-january---march-2026--q1-,c4351845The following files are available for download:
More news about: Implantica
May 22, 2026, 02:00 ET Hugel highlights global vision for K-aesthetics
three major botulinum toxin markets — the U.S., China, and Europe," she said. "With a presence in more than 70 countries and strong manufacturing and R&D capabilities, Hugel has tremendous long-term growth potential. The company also benefits from being rooted in Korea, which has emerged as a global
More news about: Hugel
May 22, 2026, 01:45 ET Changan and Kawa achieve a significant milestone with a US$950 million investment and the launch of technologically innovative flexible fuel technology
achievement, Changan aims to leverage its extensive engine expertise to launch hybrid and electric models, further strengthening local supply chains and R&D capabilities. The company also plans to open more than 60 dealerships by 2026, continuing its global expansion and advancing smart and sustainable
More news about: Changan Group
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
announced the preliminary PoC clinical study results for its global first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO)
More news about: Innovent Biologics
May 21, 2026, 22:40 ET 【2026 ASCO】亞盛醫藥公佈多項臨床進展，三項獲快速口頭報告
這項多中心、開放標簽的Ib期研究探索了奧雷巴替尼與貝林妥歐單抗聯合方案在復發/難治（R/R）Ph+ BCP-ALL或CML-LBP患者中的應用。入組時存在陽性可測量的殘留疾病（MRD）且非完全緩解（CR）的5例患者組中，4例達到CR，2例實現MRD轉陰，整體安全性可控。這項研究首次在國際患者群體中驗證了奧雷巴替尼聯合免疫療法在CML-LBP與R/R Ph+ BCP- ALL中的可行性。Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic
More news about: 亞盛醫藥
May 21, 2026, 20:05 ET 11 Greenberg Traurig Lawyers Recognized in 2026 Lawdragon 100 Leading Immigration Lawyers Guide
Dillon R. Colucci — Immigration, Individuals, Families, Business
More news about: Greenberg Traurig, LLP
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
NSCLC.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
announces updated data from the Phase 1 PoC clinical study of its first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical
More news about: Innovent Biologics
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
investigated as a next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager, as monotherapy in a cohort of heavily pre-treated BCMA-exposed R/R MM patients will be presented at the meeting.Etentamig is an investigational BCMA and CD3 bispecific antibody T-cell engager composed
More news about: AbbVie
May 21, 2026, 18:10 ET Crime organizado tem margem de lucro de até 500% com contrabando do Paraguai e movimenta R$ 60 bilhões por ano no Brasil, aponta estudo IDESF
content:https://www.prnewswire.com/br/comunicados-para-a-imprensa/crime-organizado-tem-margem-de-lucro-de-ate-500-com-contrabando-do-paraguai-e-movimenta-r-60-bilhoes-por-ano-no-brasil-aponta-estudo-idesf-302779624.htmlFONTE
More news about: IDESF (Instituto de Desenvolvimento Econômico e Social de Fronteiras)
May 21, 2026, 18:03 ET Coupa Acquires Tonkean to Accelerate Agentic Intake and Orchestration for Global Trade
guarantee compliance while maximizing adoption—all without any change management and no code. Founded in 2015, Tonkean is headquartered in Palo Alto with R&D in Tel Aviv. Tonkean investors include Foundation Capital, Magma, Lightspeed, and Accel.Logo -
More news about: Coupa Software
May 21, 2026, 17:45 ET Coupa Acquires Tonkean to Accelerate Agentic Intake and Orchestration for Global Trade
guarantee compliance while maximizing adoption—all without any change management and no code. Founded in 2015, Tonkean is headquartered in Palo Alto with R&D in Tel Aviv. Tonkean investors include Foundation Capital, Magma, Lightspeed, and Accel.
More news about: Coupa Software
May 21, 2026, 17:30 ET Rutgers Cancer Institute and RWJBarnabas Health to Highlight Advances Shaping the Future of Cancer Research at the 2026 ASCO Annual Meeting
Meeting, taking place May 29–June 2 in Chicago and online. Highlights include findings from a late-breaking abstract, Neo-adjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial, scheduled for presentation on June 1
More news about: Rutgers Cancer Institute and RWJBarnabas Health
May 21, 2026, 17:30 ET Canopy Studies Selected for Oral and Poster Presentations at 2026 ASCO Annual Meeting
Society of Hematology (ASH) Annual Meeting.3 Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring
More news about: Canopy
May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations such as G1202R. In addition, neladalkib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and
More news about: Nuvalent, Inc.